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Tumor sections from nonneoplastic (n = 15), benign (n = 28), and malignant ovarian tumors (n = 20) were obtained from 63
women. Immunohistochemistry of the tumor sections demonstrated that inducible nitric oxide synthase (iNOS) expression was
increased in ovarian cancer samples compared to nonneoplastic or benign tumor samples. Using the Griess method, nitric oxide
(NO) metabolite levels were also found to be elevated in malignant tumor samples compared to benign tumor samples (P<.05).
For stage I ovarian cancer, intracystic NO levels >80μM were more frequent than NO levels <80μM, and iNOS expression in
well-diﬀerentiated carcinomas was greater than in moderately/poorly diﬀerentiated carcinomas (P<.05). These data suggest an
important role for NO in ovarian carcinogenesis.
Copyright © 2008 Rosekeila Sim˜ oes Nomelini et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Ovarian cancer is the eighth most frequent malignant
neoplasia and the ﬁfth most common cause of death
from malignant tumor growth in women in the US [1].
The frequency of ovarian cancer increases in each decade
of life, with the highest rate of diagnosis occurring in
women that are 75 years of age [2]. Early diagnosis of
o v a r i a nt u m o r si sd i ﬃcult since tumors with diameters
less than 5cm cannot be recognized by bimanual pelvic
examination [3, 4]. However, pelvic examination, ultra-
sonography, detection of tumor markers (such as CA 125,
CA 15.3, CA 72.4, and CA 19.9), as well as color Doppler
imaging have been shown to be useful in the diagnosis
of ovarian cancer, despite the limitations of these methods
in diﬀerentiating between benign and malignant tumors
[5].
Nitric oxide (NO) is a biological messenger synthe-
sized from L-arginine by nitric oxide synthase (NOS).
The endothelial and neuronal isoforms of NOS (eNOS
and nNOS, resp.) are constitutively expressed in many cell
types, however, inducible NOS (iNOS) is only induced in
leukocytes,endothelialcells,andotherspeciﬁccelltypesafter
stimulation by bacterial endotoxins or cytokines, resulting in
higher concentrations of NO [6].
NO can also exert both pro- and antitumor eﬀects in the
tumormicroenvironment.ProductionofNOisamechanism
by which activated endothelium can lyse tumor cells [7],
however, it can also regulate tumor growth and metastasis
depending on its concentration [8, 9]. Data from previous
studies also suggest that NO is both cytotoxic and cytostatic
against microorganisms and malignant cells [10, 11]w i t h
synthesis of NO by malignant cells causing NO-mediated
apoptosis [12] .A saf r e er a d i c a l ,N Oc a nr e a c tt op r o d u c e
peroxynitrites which can directly and indirectly cause DNA
damage [12]. If produced for a long period of time, excess
NO production can lead to mutations and ultimately to
cancer [13, 14]. In addition to increasing the metastatic
potential of tumor cells via mutations in the DNA, NO
production by neoplastic cells promotes angiogenesis, an2 Mediators of Inﬂammation
essential process for the growth and maintenance of tumors
[15, 16].
Understanding the role of iNOS in ovarian cancer would
provide valuable insight into the development of additional
therapeutic options. The aim of the present study was to
identify diﬀerences between iNOS expression and the local
production of NO in patients with varying stages and grades
of ovarian cystic tumors. Therefore, levels of intracystic
NO metabolites and expression of iNOS were analyzed in
tumor sections from patients with nonneoplastic, benign, or
malignant ovarian tumors.
2. MATERIALS AND METHODS
2.1. Patientsandpathologicalassessment
This study enrolled 63 randomly selected women who
received pelvic mass outpatient services from the Discipline
of Gynecology and Obstetrics of the Federal University of
Triˆ angulo Mineiro (UFTM), Uberaba, Brazil. These patients
underwent surgery for an adnexal mass between February
1996andFebruary2007,andinformedconsentwasobtained
from patients to allow their tissue to be used for examination
and related experiments. This study was approved by the
UFTM Research Ethics Committee.
Candidates for exploratory surgery were characterized
by one or more of the following criteria: cysts with ≥1
thick septum (>3mm) or ≥2 thin septa, a cyst diameter
≥7cm, persistence or increase in the cyst or ovarian volume
over a minimum of two follow-up periods, the presence of
vegetation or calciﬁcation, a solid or predominantly solid
tumor, ascites, elevated serum levels of tumor markers, or a
resistance index ≤0.4 as detected by color Doppler imaging
[3, 5]. Inclusion criterion was the anatomicopathological
ﬁnding of an ovarian tumor (primary neoplastic or nonneo-
plastic tumor). Exclusion criteria were adnexal torsion, cyst
rupture, metastasis of another primary tumor, or previous
chemotherapy. The anatomicopathological evaluation and
staging of all cases were performed according to guidelines
published by the World Health Organization (WHO) and
the International Federation of Gynecology and Obstetrics
(FIGO) [17, 18]. Patients were divided into 3 groups
according to the classiﬁcation of tumor type: nonneoplastic
(n = 15), benign (n = 28), or malignant (n = 20)
(which included cystadenomas of borderline malignancy).
Characterization of patient groups is presented in Table 1.
2.2. Collectionofintracysticﬂuid
Cystic ﬂuid samples were aseptically collected by punc-
tion immediately following resection of tissue. Bloody
ﬂuids caused by punction were excluded from analysis.
The collected ﬂuids were immediately stored on ice until
centrifugation (180× g, 15 minutes) was performed. Cell
supernatants were transferred to fresh tubes, and the cell
pelletswereresuspendedinphosphate-buﬀeredsaline(PBS).
Both samples were stored at −70
◦C until needed [19].
2.3. Determinationofnitrateconcentration
The levels of NO metabolites (nitrite plus nitrate) in cystic
samples were determined by enzymatically reducing the
nitrate present with nitrate reductase as previously described
[20]. Brieﬂy, 50μL of nondiluted sample was incubated
with an equal volume of reductase buﬀer (0.1M potassium
phosphate (pH 7.5), 1mM NADPH, 10mM FAD, 4U of
nitrate reductase/mL) for 20 hours at 37
◦C. A standard
nitrate curve was obtained by incubating sodium nitrate
(10 to 200μM) with reductase buﬀer. The total amount of
nitrite was determined by the Griess method [21]. Brieﬂy,
the samples were incubated with an equal volume of freshly
prepared Griess reagent (1% sulfanilamide, 0.1% naph-
thylenediamine dihydrochloride in 5% phosphoric acid).
Absorbance at 550nm was determined using a multi-well
plate reader (Multiskan MCC/340MKII, Flow Laboratories)
and the results were reported as micromoles of NO3 +NO 2.
2.4. Immunohistochemistry
Specimens obtained from surgical resection were ﬁxed in
10% formalin before being processed in paraﬃn. Sections
stained with hematoxylin-eosin were reviewed by a pathol-
ogist and a representative section for each case was selected
for immunohistochemical analysis.
Selected sections were deparaﬃnized, rehydrated, and
heated in a microwave oven in 0.01M citrate buﬀer (pH 6.0)
for 30 minutes. Endogenous peroxidase activity was blocked
by 3% hydrogen peroxide for 10 minutes, followed by a
wash with PBS. The sections were incubated overnight at
4◦C with an anti-iNOS rabbit polyclonal antibody (Santa
Cruz Biotechnology, 1:200). The conjugate used was the
avidin-biotin peroxidase detection solution (Dako Cytoma-
tion LSAB and System-HRP). The signal was visualized
using diaminobenzidine (Dako Cytomation Liquid DAB
and substrate Chromogen System, Dako). Slides were coun-
terstained with Harris’s haematoxylin, dehydrated, cleared,
and mounted. A skin sample with chronic granulomatous
inﬂammation known to be positive for iNOS was used as
a positive control. Two independent observers evaluated
the sections and the intensity of staining was evaluated
subjectively using the following designations: 0 (no signal),
1( w e a k ) ,2( m e d i u m ) ,3( s t r o n g )[ 22]. When scores of
multiple tissue stainings were combined, scores that were ≤1
were labeled “weak intensity”, and scores ≥2 were labeled
“strong intensity”.
2.5. Statisticalanalysis
Data were analyzed using GraphPad Instat software. For
immunohistochemical staining, the concordance between
staining intensity scores was calculated according to the
following classiﬁcations: kappa <0.4: slight concordance;
kappa ≥0.4 and <0.8: moderate concordance; kappa ≥0.8
and <1: strong concordance; kappa = 1: perfect concordance.
The ﬁrst inter-rater agreement was 90.7% (kappa = 0.94).
All discordant cases were re-evaluated and the result deter-
mined by consensus. The Fisher’s exact test was used toRosekeila Sim˜ oes Nomelini et al. 3
Table 1: Characteristics of the three-patient groups compared in this study.
Nonneoplastic tumors (n = 15) Benign neoplasias (n = 28) Malignant neoplasias (n = 20)
Age (years, mean ± SD) 42.8 ±7.03 7 .1 ±14.64 6 .9 ±14.9
Parity child (mean ± SD) 2.3 ±1.52 ±1.83 .1 ±2.8
Smokers 4 (26.7%) 7 (25.0%) 9 (45.0%)
Race:
Caucasian women 12 (80.0%) 17 (60.7%) 17 (85.0%)
Non-Caucasian women 3 (20.0%) 11 (39.3%) 3 (15.0%)
Use of hormonal
contraception 2 (13.3%) 5 (17.9%) 2 (10.0%)
Tubal ligation 3 (20.0%) 3 (10.7%) 4 (20.0%)
Hormonal status:
Reproductive age (years) 12 (80.0%) 23 (82.1%) 10 (50.0%)
In menopause 3 (20.0%) 5 (17.9%) 10 (50.0%)
Table 2: Immunohistochemical staining of iNOS in nonneoplastic, benign, and malignant ovarian tissue samples.
Strong intensity of iNOS expression(a) Weak intensity of iNOS expression(b)
Nonneoplastic tumors (n = 15) 5 (33.3%) 10 (66.7%)
Benign neoplasia (n = 21) 6 (28.6%) 15 (71.4%)
Malignant neoplasia (n = 18)
∗+ 16 (88.9%) 2 (11.1%)
(a) Received a score of 2-3 for intensity of iNOS expression.
(b) Received a score of 0-1 for intensity of iNOS expression.
∗P = .0014 compared to nonneoplastic tumor samples.
+P = .0003 compared to benign neoplasia samples (Fisher’s exact test).
compare iNOS immunohistochemistry results and to assess
the relationship between iNOS expression and NO levels
with the stage and grade of the ovarian cancer samples
analyzed. Data for nitrate levels were expressed as the mean
+/− standard deviation (SD) and values were compared by
ANOVA followed by the Tukey test for individual compar-
isons. The correlation between intracystic nitrate levels and
iNOS immunolabeling was tested using Spearman’s rank
correlation coeﬃcient. The signiﬁcance level was set at less
than 0.05.
3. RESULTS
3.1. Patients
Sixty-three randomly selected women receiving pelvic mass
outpatient services from the Discipline of Gynecology and
Obstetrics of the Federal University of Triˆ angulo Mineiro
(UFTM) were enrolled in this study. For those diagnosed
with nonneoplastic tumors (n = 15), 10 (66.7%) had serous
ovarian cysts and 5 (33.3%) had functional cysts (corpus
luteum, follicular, and theca lutein cysts). The 28 patients
diagnosed with benign neoplasias included 11 (39.3%) with
serouscystadenoma,6(21.4%)withmucinouscystadenoma,
6(21.4%)withmatureteratoma,3(10.7%)withcystadenoﬁ-
broma, as well as 1 (3.6%) with serous- and 1 (3.6%) with
mucinous-cystadenoma associated with Brenner’s tumor.
For the 20 patients diagnosed with malignant neoplasias,
the cases included 7 (35%) serous adenocarcinoma, 3 (15%)
granulosa cell tumor, 3 (15%) mucinous cystadenoma of
borderline malignancy, 2 (10%) mucinous cystadenocar-
cinoma, 1 (5%) endometrioid adenocarcinoma, 1 (5%)
granulosacelltumorassociatedwithBrenner’stumor,1(5%)
anaplasic adenocarcinoma, 1 (5%) immature teratoma with
epidermoid carcinoma, and 1 (5%) serous cystadenoma of
borderline malignancy. In the ovarian cancer patient group,
the number of each tumor stage resected included 5 (25%)
of I-A, 1 (5%) of I-B, 2 (10%) of I-C, 1 (5%) of III-A, 10
(50%) of III-C, and 1 (5%) of IV. In the III-C and IV stages,
ﬁve complete surgeries, four satisfactory citorreductions
and only 2 unsatisfactory citorreductions were performed.
Patients receiving adjuvant ﬁrst-line chemotherapy received
either a combination of cisplatin, epirubicin, and cyclophos-
phamide for epithelial tumors, or cisplatin, etoposide, and
bleomycin for granulosa cell tumors of stages ≥I-B. Of the
12 carcinomas, 5 (41.7%) were well diﬀerentiated, 4 (33.3%)
were moderately diﬀerentiated, and 3 (25%) were poorly
diﬀerentiated. Five patients were diagnosed with malignant
ovarian tumors had died before their follow-up.
3.2. iNOSimmunohistochemistry
There were suﬃc i e n ts a m p l e st op e r f o r mi N O Si m m u n o h i s -
tochemistry on 15 nonneoplastic tumors, 21 benign tumors,
and 18 malignant tumors (Figures 1 and 2). The results are
summarized in Table 2. Samples with strong iNOS staining
(scored ≥2) were more frequently found in ovarian cancer
samples than in nonneoplastic (P = .0014) or benign
neoplasia samples (P = .0003).4 Mediators of Inﬂammation
500μm
Figure 1: Immunohistochemistry negative staining of anti-iNOS
polyclonal antibody (serous ovarian cyst, 400x, diaminobenzidine).
500μm
Figure 2: Immunohistochemistry positive staining of anti-
iNOS polyclonal antibody (serous cystadenocarcinoma, 400x,
diaminobenzidine).
Samples of malignant ovarian cancer tissue were further
classiﬁed into well-diﬀerentiated (n = 11) or moder-
ately/poorly diﬀerentiated (n = 7) tumors. For the well-
diﬀerentiated tumors, 8 (72.7%) presented strong staining of
iNOS while the other 3 presented weak or medium staining
of iNOS. For the moderately/poorly diﬀerentiated tumor
samples, all showed weak/medium intensity of iNOS. Over-
all, well-diﬀerentiated tumors presented a higher frequency
of strong iNOS expression compared to moderately/poorly
diﬀerentiated carcinomas (P = .004; Fisher’s exact test). No
statistically signiﬁcant correlation was found between the
intensity of iNOS staining and tumor stage.
Of the 5 (27.8%) patients diagnosed with malignant
ovarian tumors that had died by the time of follow-up,
only one of the samples previously collected from those ﬁve
individuals showed strong expression for iNOS.
3.3. Cysticﬂuidnitrateconcentration
Cystic ﬂuid samples were collected at the time of surgical
resection and were subsequently tested for NO metabolite
levels. Cystic ﬂuids from 1 nonneoplastic tumor, 1 benign
neoplasia, and 2 malignant ovarian tumors were not tested
due to the viscous consistency of those ﬂuids. The mean
levels of NO metabolites detected in the malignant tumor
samples (75.7μM, n = 18) were signiﬁcantly higher (P =
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Figure 3: NO metabolite levels determined from cystic ﬂuid
samples obtained from patients with nonneoplastic tumors (n =
14), benign tumors (n = 27), and malignant neoplasias (n = 18).
P = .045 (ANOVA); ∗P<. 05 versus benign neoplasia (Tukey).
.045) than the NO metabolite levels for benign ovarian
tumors (38.5μM, n = 27). However, statistically signiﬁcant
diﬀerenceswerenotdetectedbetweenNOlevelsofmalignant
neoplasia samples versus nonneoplastic samples (40.9μM,
n = 14) (Figure 3).
To examine whether intracystic NO metabolite levels
could be predictive for tumor stage, patient samples were
divided into two groups: those with NO metabolite levels
<80μM and those with NO metabolite levels >80μM. The
value of 80μM was derived from the median value of NO
detected in malignant tumor samples (81.6μM). No stage II
samples had detectable levels of NO metabolites. For stage
I samples, 6 (85.7%) had NO metabolite levels >80μM,
and only 1 (14.3%) had NO metabolite levels <80μM. In
contrast, 3 of stage III/IV tumor samples (27.3%) had NO
metabolite levels >80μM and 8 (72.7%) had NO metabolite
levels <80μM. These results indicate that intracystic NO
metabolite levels >80μM were signiﬁcantly more frequent
in stage I samples than in stage III/IV samples (P =
.0498; Fisher exact test). However, there was no signiﬁcant
correlation between NO metabolite levels and the grade of
tumor diﬀerentiation.
3.4. iNOSimmunoreactivityandNOmetabolitelevels
Correlations between NO production and iNOS expression
in the collected tumor tissues are summarized in Table 3.
Cystic levels of NO did not correlate with iNOS expression
in ovarian tissues.
4. DISCUSSION
Diﬀerences in iNOS expression between nonneoplastic,
benign and malignant ovarian neoplasias suggest a role for
NO in ovarian carcinogenesis. Our experiments revealed
greater expression of iNOS in malignant ovarian neo-
plasias than in benign or nonneoplastic tumors. There
were two cases of ovarian cancer that did not show iNOSRosekeila Sim˜ oes Nomelini et al. 5
Table 3: Correlation between iNOS immunostaining and NO metabolite levels detected in tissue samples collected using Spearman’s rank
correlation coeﬃcient.
Groups analyzed iNOS immunostaining × NO metabolite levels
Nonneoplastic tumors (n = 14) r = 0.1595, P = .586
Benign neoplasia (n = 20) r = 0.0942, P = .693
Malignant neoplasia (n = 16) r = 0.1188, P = .661
immunoreactivity, while approximately one-third of benign
and nonneoplastic tumor samples were positive for iNOS
expression. Our results are consistent with other studies that
have shown that a majority of ovarian malignant neoplasias
presentNOSactivity,whileiNOSisdetectedatlowerlevelsin
patients without cancer [23]. Although we hypothesize that
iNOS may be a marker to detect malignant disease, it is not
considered by others to be a marker exclusive to malignant
disease [24].
Expression of NOS in malignant tissue derived from
gynecological, breast, central nervous system, gastric, and
colorectal tumors has been reported, suggesting its role in
cancer progression [25–29]. A positive correlation between
iNOS expression and an increased density of tumor
microvessels in human colorectal cancer was shown by
Cianchi et al. [28], and iNOS expression has been asso-
ciated with increased vascularization and tumor invasion
in endometrial malignant neoplasia [30]. Correspondingly,
patients with lung cancer, prostate cancer, or cervical cancer
treated with NO inhibitors showed antivascular activity
[31]. These data support the hypothesis that the inhibition
of iNOS may provide a new therapeutic option for the
treatment of ovarian cancer [32].
Recently, it was demonstrated that iNOS expression
in serous and low-grade carcinomas was signiﬁcantly
higher than in nonserous and high-grade carcinomas [22].
Advanced stage tumors expressed low levels of iNOS and
were associated with a shorter mean survival time although
this was not determined to be a statistically signiﬁcant
correlation. In our study, patients with malignant tumors
had signiﬁcantly higher levels of intracystic NO and iNOS
expression in well-diﬀerentiated carcinomas compared to
moderately/poorly diﬀerentiated carcinomas. In addition,
positive iNOS expression in ovarian carcinoma had been
identiﬁedasapositivedisease-relatedsurvivalindicator[33],
and was found to be consistent with the high levels of iNOS
activity and NO production of nonmetastatic cells versus
metastatic cells [34].
In contrast to our ﬁndings, a separate study found that
patients with advanced ovarian serous tumors express iNOS
andCOX-2andexperienceashorterdisease-freeintervaland
survival rate [35]. In addition, patients negative for iNOS
expression presented a complete clinical response to a ﬁrst-
line treatment of chemotherapy. A separate study found a
positive correlation of NO synthesis with tumor progression
in a breast cancer model [25].
In a study by Taveres-Murta et al., increased levels of
NO metabolites in the tumor microenvironment were found
in patients with ovarian cancer, but not in patients with
benign neoplasia [19]. Similarly, supernatantsof cellcultures
obtainedfromwell-diﬀerentiated,malignantovariantumors
were found to contain higher levels of NO metabolites
compared to cell cultures from patients with poorly diﬀer-
entiated tumors [36]. However, to our knowledge, this is
the ﬁrst study to evaluate both intracystic NO production
and iNOS expression from the same tumor tissue. Our
results suggest that intracystic NO is not produced by tumor
cells since no signiﬁcant correlation was found between
the levels of NO metabolites detected and the intensity of
iNOS expression detected by immunohistochemical staining
of the tumor tissue. Instead, an analysis of NO production
from eﬀusions (ascitic, cystic, or pleural ﬂuids) of ovarian
malignant tumors showed a signiﬁcant correlation between
the percentage of macrophages present and detectable levels
of NO metabolites, suggesting that macrophages play a
signiﬁcant role in the production of NO in the tumor
microenvironment [36].
An association between increased intracystic leukocyte
inﬁltratesandNOproductionhaspreviouslybeenassociated
with ovarian cancer [19]. NO produced by ovarian carci-
noma cell lines has also been shown to correlate with the
extent of tumor cell apoptosis observed [12]. These results,
in combination with our data, suggest that the level of iNOS
expressed by tumor cells and inﬁltrating leukocytes accounts
for the intracystic NO production detected although it
cannot be ruled out that the iNOS associated with ovarian
tumors could also be expressed by immune cells [36, 37].
Studies using activated macrophages treated with NOS-
speciﬁc inhibitors have shown an inhibition of NO pro-
duction and induced cytotoxicity, suggesting that activated
macrophages may mediate NO-dependent cytotoxicity [13].
High concentrations of NO can mediate cytotoxic activ-
ity against tumor cells, while low concentrations have been
associated with angiogenesis. High levels of NO have also
been shown to induce apoptosis. Correspondingly, high
concentrations of NO have not been found to be maintained
in many malignant neoplasias [38]. These opposing actions
of NO have been attributed to factors such as diﬀerences in
the isoform of NOS expressed, the level of NOS expression,
and the type of cell involved in either in vitro or in vivo
systems [39].
In ovarian cancer cell lines, high levels of NO donors or
strong expression of the iNOS suppressed survivin levels (a
human gene that is part of the inhibitor of apoptosis family),
and have been shown to induce apoptosis. It is hypothesized
that NO signaling could contribute to therapy resistance in
epithelial ovarian cancer by modulating survivin expression
since low levels of NO are associated with resistance to
carboplatin- and paclitaxel-induced apoptosis [40]. The
ability to modulate NOS gene expression may represent an6 Mediators of Inﬂammation
opportunity to control the growth and metastasis of tumors
in vivo [13].
5. CONCLUSIONS
In this study, increased expression of iNOS and increased
production of NO metabolites were detected in the tumor
microenvironment of ovarian cancer samples compared
to benign and nonneoplastic ovarian tissue samples. For
ovarian cancer samples, iNOS expression correlated with
the extent of tumor diﬀerentiation and intracystic NO
metabolite levels correlated with the tumor stage. We
hypothesize that the absence of a correlation between NO
production and iNOS expression indicates that diﬀerent cell
types are involved in iNOS expression, and that controlling
NO production and inducing NOS may represent valuable
strategies in the prevention of benign tissue transitioning
into well-diﬀerentiated malignant ovarian tumors.
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